Genfit (GNFT) Q1 2025 earnings summary

Executive summary

• Cash and cash equivalents reached €129.5 million as of March 31, 2025, up from €74.0 million a year earlier and €81.8 million at December 31, 2024, mainly due to a €130 million non-dilutive royalty financing agreement with HCRx, partially offset by €61.7 million spent on repurchasing convertible debt.

• Revenues for Q1 2025 were €2.8 million, up from €1.1 million in Q1 2024, driven by royalties from Ipsen's sales of Iqirvo® (elafibranor).

• GENFIT continues to invest in R&D, focusing on its ACLF franchise and other rare liver disease programs.

Financial highlights

• Q1 2025 revenues increased to €2.8 million from €1.1 million in Q1 2024, reflecting higher royalty income.

• Cash position as of March 31, 2025, was €129.5 million, significantly higher than both the prior quarter and prior year.

• Convertible debt nominal amount stands at €586 thousand as of the press release date.

Outlook and guidance

• Cash runway is projected to extend beyond the end of 2027, assuming receipt of future milestone revenues from Ipsen, full drawdown of royalty financing, and reimbursement of remaining OCEANEs at maturity.

• Expectation of significant future milestone payments, including a €26.5 million payment following Iqirvo® pricing and reimbursement approval in Italy.